Nanopharmaceuticals (part 2): Products in the Pipeline

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2015 Feb 25

PMID 25709446

Citations 27

Authors

Volkmar Weissig

Diana Guzman-Villanueva

Affiliations

Soon will be listed here.

Abstract

In part I of this review we assessed nanoscience-related definitions as applied to pharmaceuticals and we discussed all 43 currently approved drug formulations, which are widely publicized as nanopharmaceuticals or nanomedicines. In continuation, here we review the currently ongoing clinical trials within the broad field of nanomedicine. Confining the definition of nanopharmaceuticals to therapeutic formulations, in which the unique physicochemical properties expressed in the nanosize range, when man-made, play the pivotal therapeutic role, we found an apparently low number of trials, which reflects neither the massive investments made in the field of nanomedicine nor the general hype associated with the term "nano." Moreover, after an extensive search for information through clinical trials, we found only two clinical trials with materials that show unique nano-based properties, ie, properties that are displayed neither on the atomic nor on the bulk material level.

Citing Articles

Metal-based nanoparticle in cancer treatment: lessons learned and challenges.

Hheidari A, Mohammadi J, Ghodousi M, Mahmoodi M, Ebrahimi S, Pishbin E Front Bioeng Biotechnol. 2024; 12:1436297.

PMID: 39055339 PMC: 11269265. DOI: 10.3389/fbioe.2024.1436297.

Conjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for early cancer diagnosis: study.

Rahmani R, Darroudi M, Gharanfoli M, Chamani J, Gholamin M, Hashemi M Iran J Basic Med Sci. 2022; 25(10):1234-1242.

PMID: 36311203 PMC: 9588323. DOI: 10.22038/IJBMS.2022.65590.14430.

The evolving regulatory landscape in regenerative medicine.

Beetler D, Di Florio D, Law E, Groen C, Windebank A, Peterson Q Mol Aspects Med. 2022; 91:101138.

PMID: 36050142 PMC: 10162454. DOI: 10.1016/j.mam.2022.101138.

Molecular Switches-Tools for Imparting Control in Drug Delivery Systems.

Fitzmaurice O, Bartkowski M, Giordani S Front Chem. 2022; 10:859450.

PMID: 35433638 PMC: 9008311. DOI: 10.3389/fchem.2022.859450.

Need for Expansion of Pharmacy Education Globally for the Growing Field of Nanomedicine.

Barton A, Borchard G, Wacker M, Pastorin G, Saleem I, Chaudary S Pharmacy (Basel). 2022; 10(1).

PMID: 35202067 PMC: 8878512. DOI: 10.3390/pharmacy10010017.

References

Bao C, Conde J, Polo E, Del Pino P, Moros M, Baptista P . A promising road with challenges: where are gold nanoparticles in translational research?. Nanomedicine (Lond). 2014; 9(15):2353-70. DOI: 10.2217/nnm.14.155. View

Balakrishnan V, Rao M, Kausz A, Brenner L, Pereira B, Frigo T . Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest. 2009; 39(6):489-96. DOI: 10.1111/j.1365-2362.2009.02130.x. View

Kopecek J, Rejmanova P, Duncan R, Lloyd J . Controlled release of drug model from N-(2-hydroxypropyl)-methacrylamide copolymers. Ann N Y Acad Sci. 1985; 446:93-104. DOI: 10.1111/j.1749-6632.1985.tb18393.x. View

Duncan R . Biological effects of soluble synthetic polymers as drug carriers. Crit Rev Ther Drug Carrier Syst. 1985; 1(4):281-310. View

Kopecek J . Controlled biodegradability of polymers--a key to drug delivery systems. Biomaterials. 1984; 5(1):19-25. DOI: 10.1016/0142-9612(84)90062-0. View

Molday R, Molday L . Separation of cells labeled with immunospecific iron dextran microspheres using high gradient magnetic chromatography. FEBS Lett. 1984; 170(2):232-8. DOI: 10.1016/0014-5793(84)81319-8. View

Pottier A, Borghi E, Levy L . New use of metals as nanosized radioenhancers. Anticancer Res. 2014; 34(1):443-53. View

Schroeter M, Franke C, Stoll G, Hoehn M . Dynamic changes of magnetic resonance imaging abnormalities in relation to inflammation and glial responses after photothrombotic cerebral infarction in the rat brain. Acta Neuropathol. 2001; 101(2):114-22. DOI: 10.1007/s004010000262. View

Conde J, Dias J, Grazu V, Moros M, Baptista P, de la Fuente J . Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine. Front Chem. 2014; 2:48. PMC: 4097105. DOI: 10.3389/fchem.2014.00048. View

10.

Paul K, Frigo T, Groman J, Groman E . Synthesis of ultrasmall superparamagnetic iron oxides using reduced polysaccharides. Bioconjug Chem. 2004; 15(2):394-401. DOI: 10.1021/bc034194u. View

11.

Maggiorella L, Barouch G, Devaux C, Pottier A, Deutsch E, Bourhis J . Nanoscale radiotherapy with hafnium oxide nanoparticles. Future Oncol. 2012; 8(9):1167-81. DOI: 10.2217/fon.12.96. View

12.

Ringsdorf H . [Macromolecular compounds as potential protective agents against ionizing rays]. Strahlentherapie. 1967; 132(4):627-35. View

13.

Bourrinet P, Bengele H, Bonnemain B, Dencausse A, Idee J, Jacobs P . Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest Radiol. 2006; 41(3):313-24. DOI: 10.1097/01.rli.0000197669.80475.dd. View

14.

Bullivant J, Zhao S, Willenberg B, Kozissnik B, Batich C, Dobson J . Materials characterization of Feraheme/ferumoxytol and preliminary evaluation of its potential for magnetic fluid hyperthermia. Int J Mol Sci. 2013; 14(9):17501-10. PMC: 3794737. DOI: 10.3390/ijms140917501. View

15.

Lodhia J, Mandarano G, Ferris N, Eu P, Cowell S . Development and use of iron oxide nanoparticles (Part 1): Synthesis of iron oxide nanoparticles for MRI. Biomed Imaging Interv J. 2011; 6(2):e12. PMC: 3097763. DOI: 10.2349/biij.6.2.e12. View

16.

Jahn M, Andreasen H, Futterer S, Nawroth T, Schunemann V, Kolb U . A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011; 78(3):480-91. DOI: 10.1016/j.ejpb.2011.03.016. View

17.

Bradbury M, Phillips E, Montero P, Cheal S, Stambuk H, Durack J . Clinically-translated silica nanoparticles as dual-modality cancer-targeted probes for image-guided surgery and interventions. Integr Biol (Camb). 2012; 5(1):74-86. PMC: 4428677. DOI: 10.1039/c2ib20174g. View

18.

Batz H, Franzmann G, Ringsdorf H . Model reactions for synthesis of pharmacologically active polymers by way of monomeric and polymeric reactive esters. Angew Chem Int Ed Engl. 1972; 11(12):1103-4. DOI: 10.1002/anie.197211031. View

19.

Cobley C, Au L, Chen J, Xia Y . Targeting gold nanocages to cancer cells for photothermal destruction and drug delivery. Expert Opin Drug Deliv. 2010; 7(5):577-87. PMC: 2858262. DOI: 10.1517/17425240903571614. View

20.

Weissig V, Pettinger T, Murdock N . Nanopharmaceuticals (part 1): products on the market. Int J Nanomedicine. 2014; 9:4357-73. PMC: 4172146. DOI: 10.2147/IJN.S46900. View